Home Biosimilar Antibodies Immunology & Inflammation IFN -IFNAR Anifrolumab (Anti-IFNAR1)
For research use only. Not for use in humans.

Anifrolumab (Anti-IFNAR1)

Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD.

Anifrolumab (Anti-IFNAR1)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.001mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD.

Product Details

CAS No. 1326232-46-5
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07691970 NOT_YET_RECRUITING Drug: Anifrolumab Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus AstraZeneca 2026-09-01 PHASE3
NCT07630714 NOT_YET_RECRUITING Systemic Lupus Erythematosus AstraZeneca 2026-07-28 PHASE2
NCT07688980 NOT_YET_RECRUITING Systemic Lupus Erythematosus AstraZeneca 2026-10-30 PHASE1
NCT07611214 RECRUITING Drug: LUPKYNIS|Drug: mycophenolic acid analog (MPAA)|Drug: c Lupus Nephritis Aurinia Pharmaceuticals Inc. 2026-04-22 PHASE4
NCT07430306 RECRUITING Drug: Anifrolumab Systemic Lupus Erythematosus AstraZeneca 2026-04-13 PHASE3
NCT05835310 RECRUITING Drug: Placebo Systemic Lupus Erythematosus AstraZeneca 2024-03-14 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-09)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.